These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38606169)

  • 21. Immune checkpoint inhibitors in the management of malignancies in transplant recipients.
    Regalla DKR; Williams GR; Paluri RK
    Postgrad Med J; 2018 Dec; 94(1118):704-708. PubMed ID: 30425139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.
    Manohar S; Thongprayoon C; Cheungpasitporn W; Markovic SN; Herrmann SM
    Kidney Int Rep; 2020 Feb; 5(2):149-158. PubMed ID: 32043028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
    Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
    Kuske M; Haist M; Jung T; Grabbe S; Bros M
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review.
    Rossi E; Schinzari G; Maiorano BA; Esposito I; Acampora A; Romagnoli J; Stefani AD; Regno LD; Lancellotta V; Fionda B; Tagliaferri L; Peris K; Tortora G
    Immunotherapy; 2022 Jan; 14(1):65-75. PubMed ID: 34751039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.
    Murakami N; Mulvaney P; Danesh M; Abudayyeh A; Diab A; Abdel-Wahab N; Abdelrahim M; Khairallah P; Shirazian S; Kukla A; Owoyemi IO; Alhamad T; Husami S; Menon M; Santeusanio A; Blosser CD; Zuniga SC; Soler MJ; Moreso F; Mithani Z; Ortiz-Melo D; Jaimes EA; Gutgarts V; Lum E; Danovitch GM; Cardarelli F; Drews RE; Bassil C; Swank JL; Westphal S; Mannon RB; Shirai K; Kitchlu A; Ong S; Machado SM; Mothi SS; Ott PA; Rahma O; Hodi FS; Sise ME; Gupta S; Leaf DE; Devoe CE; Wanchoo R; Nair VV; Schmults CD; Hanna GJ; Sprangers B; Riella LV; Jhaveri KD;
    Kidney Int; 2021 Jul; 100(1):196-205. PubMed ID: 33359528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study.
    Carroll RP; Boyer M; Gebski V; Hockley B; Johnston JK; Kireta S; Tan H; Taylor A; Wyburn K; Zalcberg JR
    Lancet Oncol; 2022 Aug; 23(8):1078-1086. PubMed ID: 35809595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.
    Spain L; Higgins R; Gopalakrishnan K; Turajlic S; Gore M; Larkin J
    Ann Oncol; 2016 Jun; 27(6):1135-1137. PubMed ID: 26951628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy.
    O'Connell KA; Schmults CD
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():45-48. PubMed ID: 34855241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microwave ablation combined with anti-PD-1/CTLA-4 therapy induces an antitumor immune response to renal cell carcinoma in a murine model.
    Guo RQ; Peng JZ; Li YM; Li XG
    Cell Cycle; 2023 Jan; 22(2):242-254. PubMed ID: 35980140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tri-Site Academic Center Experience with Immunotherapy for Metastatic Skin Cancer in Solid Organ Transplant Patients.
    Berman HS; Degesys CA; Tolaymat L
    South Med J; 2023 Feb; 116(2):220-224. PubMed ID: 36724539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.
    Kawashima S; Joachim K; Abdelrahim M; Abudayyeh A; Jhaveri KD; Murakami N
    Korean J Transplant; 2022 Jun; 36(2):82-98. PubMed ID: 35919193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
    Zhang P; Zhu G; Li L; Lai G; Wang Z; Sun C; Xia W; Wu L
    Transplant Rev (Orlando); 2022 Dec; 36(4):100712. PubMed ID: 35870411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An efficient combination immunotherapy for antitumor immunity without accelerating cardiac allograft rejection.
    Miao X; Wu Z; Jiang Y; Liu H; Gong W
    Immunology; 2023 Jun; 169(2):157-166. PubMed ID: 36517459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.
    Moturi K; Sharma H; Hashemi-Sadraei N
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role for exosomes with self-antigens and immune regulatory molecules in allo- and auto-immunity leading to chronic immune injury following murine kidney transplantation.
    Itabashi Y; Ravichandran R; Bansal S; Chin C; Poulson C; Sureshbabu A; Nair SS; Perincheri S; Mohanakumar T
    Transpl Immunol; 2022 Dec; 75():101702. PubMed ID: 36038048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.